Ctrl/Cmd K

Loading stock analysis…

Explore

Stocks
Screener
IPOs
News

Tools

Backtest
Portfolio
Wealth
ITR

Learn

Guides
Methodology

Company

About
Contact
Disclosures
Privacy
Terms

© 2026 Anvest. All rights reserved.

Designed & Engineered in India·harsh@anvest.in

Disclaimer: Anvest provides financial analytics, screening simulations, and planning tools for informational and educational purposes only. Anvest is not a SEBI-registered investment advisor or broker. Nothing herein constitutes investment advice or an offer to buy/sell securities. Full details on methodology and limitations are documented under Disclosures and Terms.

Stocks›Healthcare

Anthem Biosciences Limited

ANTHEM · NSE · Healthcare · As of 30 Oct 2026Delayed / Sandbox EOD Data

₹828.80

−₹1.35 (−0.16%)(1D)

₹579.1552 Week Range₹977.55

Chart Score AI Profile Fundamentals Technicals Financials Shareholding Peers Filings

Anvest Score

58/100

Valuation

0/100

Quality

50/100

Growth

91/100

Health

100/100

Momentum

63/100

Valuation
0
Quality
50
Growth
91
Health
100
Momentum
63

Loading company profile…

Loading fundamentals…

Loading technical indicators…

Loading financial statement…

Loading shareholding…

Loading peer comparison…

Loading filings…

More Page Context

Research at a glance

Anthem Biosciences Limited with delayed price, financials, ownership context, and peer links.

Latest price

₹828.8

Market cap

₹46,597 Cr

P/E ratio

Not available

P/B ratio

15.32

Dividend yield

Not available

ROE

Not available

RSI 14

42.76

1Y return

Not available

Anthem Biosciences Limited FAQs

3 topics

ExpandCollapse

Related paths

Peer links appear when comparable names are available.

Open screener Curated screens Backtest ideas

What does the Anthem Biosciences Limited (ANTHEM) stock page cover?

Anthem Biosciences Limited on Anvest includes delayed price context, valuation ratios, a one-year price range, and section-level research data when available.

What are the current headline metrics for ANTHEM?

Anthem Biosciences Limited is currently shown with a delayed price near ₹828.8, P/E N/A.

Does the ANTHEM page provide investment advice?

No. The ANTHEM page is built for research, comparison, and planning. It does not publish buy, sell, or hold recommendations.

Keep exploring

Related insights

BIOCON

Biocon Limited · Healthcare

ONESOURCE

Onesource Specialty Pharma Limited · Healthcare

CONCORDBIO

Concord Biotech Limited · Healthcare

Eliminating Look-Ahead Bias in Indian Fundamental Backtests

Understand why using quarter-end dates (like March 31) invalidates fundamental backtests. Learn how Anvest enforces official SEBI filing delays.

AI Company ProfileSign in to generate AI briefing

AI Snapshot

Anthem Biosciences Limited provides scientific solutions through integrated contract research, development, and manufacturing services, earning revenue from these activities.

BiotechnologyFounded:2006CEO/MD:Ajay BhardwajHQ:Bengaluru, Karnataka

Business profile as of 2026-08-25

Business at a Glance

It generates revenue by offering custom synthesis, research and development, and manufacturing services for Active Pharmaceutical Ingredients (APIs), peptides, and specialty ingredients to pharmaceutical and biopharmaceutical clients worldwide.

CFO / PAT: 1.43×FY26

What Looks Strong

IPOShares trade +46.0% above the ₹570 IPO issue price.
Cash FlowOperating cash flow was 1.43× total net profit in FY26.
ValuationPrice/book is 15.4×. The valuation score is 72/100.

What to Watch

HistoryShort public market track record with limited historical filing cycles.

Segment revenue, FY26 (consolidated, as filed): CRDMO 83%; Speciality Ingredients 17%.
Share of segment profit before interest and tax, FY26: CRDMO 86%; Speciality Ingredients 14%.
This core activity represents 100% of the company's turnover.

FY26 (consolidated): revenue ₹2,124 cr; net profit ₹592 cr.
FY26 (consolidated): operating cash flow ₹844 cr (1.4× net profit); debt/equity 0.02×.
Latest quarter to Jun 2026 (consolidated): revenue ₹418 cr (down 23% year on year); net profit ₹120 cr.

Announcements include updates on analyst/institutional investor meetings and earnings call transcripts